在帕金森病中使用生物流体,神经成像和人工智能识别认知障碍
Anthaea-Grace Patricia Dennis1,2, Antonio P Strafella1,2,3,4
1Krembil Brain Institute, University Health Network (UHN), Toronto, ON, Canada.
Frontiers in neuroscience
|October 15, 2024
概括
开发用于帕金森病 (PD) 认知衰退的生物标志物至关重要. 结合血液和成像生物标志物,有望提前检测和改善PD患者认知障碍的预测.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 人工智能的人工智能
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,与显著的认知能力下降有关.
- 早期发现和预测PD认知障碍对于患者管理和治疗发展至关重要.
研究的目的:
- 审查和综合基于人工智能 (AI) 的方法,用于识别帕金森病认知障碍的生物标志物.
- 评估PD认知衰退的不同生物标志物类型和组合的诊断准确性.
主要方法:
- 对使用人工智能技术识别PD认知障碍生物标志物的研究进行文献综述.
- 分析生物标志物的性能,包括神经成像和生物流体标志物,单独和组合.
主要成果:
- 基于人工智能的方法在检测潜在生物标志物的过程中具有很高的灵敏度.
- 综合神经成像 (结构和功能MRI) 和生物流体生物标志物 (β-粉样-42,tau) 在根据认知功能对PD患者进行分类时达到高精度 (超过90%) 和AUC (超过0.90).
- 个人生物标志物类型,如MRI,也显示出有希望的结果,准确度和AUC高于80%/0.80.
结论:
- 整合不同类型的生物标志物,特别是基于血液和成像的标志物,显著提高了PD认知障碍的诊断准确性.
- 结合生物标志物的AI驱动分析为早期检测和预测帕金森病认知衰退提供了强大的策略.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.6K
相关概念视频
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Parkinson's Disease: Treatment
231
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
231
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
